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-Reactive Protein
o Identify Early Risk
or Development of
alcific Aortic Stenosis
ight Marker? Wrong Time?*
eter H. Stone, MD, FACC
oston, Massachusetts
alcific aortic valve disease is the most common acquired
alvular disorder in developed countries. Disease involve-
ent of the trileaflet aortic valve spans the spectrum from
aortic sclerosis,” characterized by valve thickening, fibrosis,
nd microscopic calcification without left ventricular out-
ow obstruction, to frank “aortic stenosis,” characterized by
ore severe involvement with limitation of valve opening
1). Aortic sclerosis is present in more than 25% of individ-
als over the age of 65 years and aortic stenosis in 2%, with
he prevalence of both manifestations dramatically increas-
ng with more advanced age (1–3). The dynamic and
nflammatory nature of calcific aortic stenosis has been well
ppreciated in recent years, and many pathobiologic features
f calcific aortic valve disease exhibit striking similarity to
oronary atherosclerosis. C-reactive protein (CRP), which
as been an extremely useful predictive biomarker of the
nflammatory process and prognosis of atherosclerosis (4), is
ncreased in subsets of patients with calcific aortic stenosis,
nd this has led to the hope that CRP could be used as well
o identify those patients likely to progress or develop severe
alcific aortic stenosis. The article by Novaro et al. (5) in this
ssue of the Journal sheds new and interesting light on some
imitations of that hope.
See page 1992
Calcific aortic valve disease, including both aortic sclero-
is and stenosis, is characterized by focal subendothelial
laque-like lesions on the aortic side of the leaflet that
xtend to the adjacent fibrosa layer (1). There is focal
xtracellular lipid accumulation with oxidatively modified
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.v
From the Cardiovascular Division, Brigham & Women’s Hospital, Harvard
edical School, Boston, Massachusetts.ow-density lipoprotein (LDL) (6). The predominant cell
ypes are inflammatory cells, including monocytes, which
nfiltrate the endothelial layer and differentiate into macro-
hages, which, in turn, take up oxidized LDL and become
oam cells (1). T lymphocytes are also prominent, which
ecome activated and release a variety of pro-inflammatory
ytokines (1,7). Matrix metalloproteinases (MMPs) are
laborated by inflammatory cells within the aortic valve
esions, which degrade various components of the extracel-
ular matrix (2). Tenascin C, a multifunctional extracellular
atrix glycoprotein, implicated in inflammation and calci-
cation, is intensely up-regulated in the deeper layers of the
tenosed aortic valves, adjacent to the calcified areas (1,8).
he central role of hypercholesterolemia in the pathogenesis
f calcific aortic valve disease is underscored by studies in
he rabbit model, where dietary cholesterol loading led to
ortic valve lesions similar to human aortic stenosis (9).
The renin-angiotensin system further contributes to the
nflammatory nature of the aortic valve lesion. Angiotensin-
onverting enzyme (ACE), as well as angiotensin II and the
ngiotensin II type-1 receptor, have been identified in aortic
clerotic lesions (1,2,10), which stimulate monocyte infil-
ration and macrophage uptake of modified LDL (2).
Calcification, the hallmark characteristic of aortic valve
tenosis, is also clearly a feature of the active inflammatory
rocess, occurring in valve regions of lipid disposition,
specially oxidized lipids, with additional stimulus provided
y macrophage- and T lymphocyte-produced cytokines
2,6). Early in the disease process, active microscopic areas
f calcification are seen colocalizing in areas of lipoprotein
ccumulation and inflammatory cell infiltration; as the
isease progresses, active bone formation is seen (1,2,11,12).
The similarity of the inflammatory, fibrotic, and calcifi-
ation processes of aortic valve disease and atherosclerosis is
einforced by the concordance of risk factors associated with
oth disease entities (2,3,13). Furthermore, the incidence of
dverse coronary events is significantly higher in patients
ith calcific aortic stenosis, even after adjustment for cardiac
isk factors and known atherosclerotic disease (1,14).
Therapies that are effective in reducing coronary artery
isease morbidity and mortality by stabilizing coronary
laque and reducing plaque inflammation may also reduce
rogression of calcific aortic stenosis. Retrospective studies
uggested that statins slow the progression of aortic valve
tenosis (15), and treatment of the hypercholesterolemic
abbit model with atorvastatin significantly reduced the
rogression of aortic valve disease (9). A recent prospective,
pen-label study found that rosuvastatin significantly re-
uced the progression of moderate to severe calcific aortic
tenosis (baseline mean valve area 1.23 cm2) in hypercho-
esterolemic patients (16); although a randomized, placebo-
ontrolled trial did not demonstrate a beneficial effect of
torvastatin on the progression of calcific aortic stenosis in
atients with more severe aortic stenosis (baseline mean
alve area 1.03 cm2) (17). These observations suggested the
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Editorial Comment November 13, 2007:1999–2001ypothesis that the inflammatory processes of aortic steno-
is, amenable to pharmacologic intervention, were earlier
tages in the evolution of aortic valve disease and that as the
alve calcified there may be a decrease in the inflammatory
tate and, hence, an inability to alter the disease’s natural
istory with statins (16).
The ACE inhibitors, which have been effective in reduc-
ng cardiovascular events in patients with coronary artery
isease, presumably by reducing endothelial inflammation
nd cholesterol accumulation, have similarly been shown in
ome (18), but not all (19), retrospective studies to reduce
he progression of valve calcification. Studies in which ACE
nhibitors did not appear to be beneficial included patients
ith more severe aortic stenosis (2).
If inflammation is the fundamental process of early aortic
alve disease, with calcification predominating in the later
tages, one might anticipate that markers of inflammation,
uch as CRP, would reflect early aortic valve disease activity
nd perhaps be less useful as a marker in later stages. The
vailable data do not support such a concept. C-reactive
rotein has been localized in the valve tissue of aortic
tenosis in both native valves and bioprosthetic aortic valves,
ith a positive correlation between serum CRP values and
alve CRP expression (20). C-reactive protein values are
ncreased in patients with severe symptomatic aortic stenosis
waiting valve surgery compared with matched controls (21)
nd decline after aortic valve replacement (22).
The study by Novaro et al. (5) in this issue of the Journal
rovides new data from a broad-based population cohort
hat the early inflammatory stages of aortic sclerosis and
ortic stenosis are not well predicted by CRP values.
-reactive protein values were obtained at study entry in
,621 subjects in the Cardiovascular Health Study and were
nvestigated cross-sectionally, to determine association with
ortic sclerosis or aortic stenosis, and longitudinally, to
etermine whether baseline CRP valves identified those
ubjects likely to develop aortic sclerosis or aortic stenosis by
chocardiography in 5-year follow-up. They observed that
lder age, male gender, hypertension, coronary artery dis-
ase, and renal insufficiency, but not CRP values, were
ssociated with the presence of increasing calcific aortic
alve abnormality and that CRP values were not related to
he progression from a normal aortic valve to aortic sclerosis
r stenosis, nor progression from aortic sclerosis to aortic
tenosis. African-American ethnicity was significantly pro-
ective from developing calcific aortic valve disease.
How do we make sense of these apparent discrepancies
hat CRP appears not to reflect the early inflammation
hase of calcific aortic valve disease but does reflect the later
alcific stages of the disease? The first methodologic con-
ideration is that the single CRP value at study entry may
ave been too distant from the time that calcific aortic
tenosis was developing during the follow-up period to
eflect the inflammatory change that would later occur. It is
lso possible that the inflammatory process in early calcific
ortic valve disease was not substantial enough to lead to anlevated serum value. It is also clear from the previously
oted associations between CRP and severe aortic stenosis
hat CRP may be a more active, direct participant in the
ater stages of the disease progression (23) and not simply a
iomarker passively reflecting the early inflammatory stages
f disease. C-reactive protein provides valuable prognostic
nformation concerning adverse cardiovascular events in
oronary disease as well (4), but it does not reflect the
resence or severity of subclinical anatomic coronary artery
isease (24,25).
The study by Novaro et al. (5) does add important new
nderstanding concerning the genetic determinants of cal-
ific aortic valve disease. Genetic characteristics of calcium
etabolism may be central to the development of valvular
alcification (26), and the observation that African Ameri-
ans were protected from development of calcific aortic
alve disease, as the authors indicate (5), may be related to
genetic predisposition toward less calcification of vascular
nd valve tissue and lower incidence of osteoporosis.
It would be of enormous value to identify a biomarker to
redict patients likely to develop aortic sclerosis and those
ikely to progress to aortic stenosis. Given the dynamic and
elatively slowly progressive inflammatory process of aortic
tenosis, pharmacologic therapies could then be directed
oward those patients at highest risk to reduce the frequency
nd severity of valve dysfunction. This paradigm of under-
tanding the development and progression of calcific aortic
tenosis, and the associated opportunities for pharmacologic
ntervention, may still be operative, but the most appropri-
te biomarker may not be CRP. C-reactive protein is
ertainly an excellent biomarker of coronary disease risk and
lso of severe aortic stenosis, but its role to reflect the early
tages of calcific aortic valve disease is much less clear. There
ill need to be many more large-scale population-based
tudies with serial CRP (and other biomarker) measure-
ents, as well as serial echoes, to identify better tracking
ools of disease progression and to guide the nature and
iming of potential pharmacologic interventions. Given the
idespread incidence of calcific aortic stenosis and the
urrent limitation of surgical intervention as the only ther-
peutic option, such a search is certainly worth pursuing.
eprint requests and correspondence: Dr. Peter H. Stone, Cardio-
ascular Division, Brigham & Women’s Hospital, 75 Francis Street,
oston, Massachusetts 02115. E-mail: pstone@partners.org.
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